Ticiana A. Leal, MD

Articles

Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

October 4th 2022

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Current Treatment Options in NSCLC

October 4th 2022

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Testing Patients with NSCLC for HER2 Mutations

September 29th 2022

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

The Role of HER2 Alterations in NSCLC

September 29th 2022

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

HER2 Alterations in NSCLC: Clinical Scenario

September 20th 2022

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Liquid vs Solid Tumor Biopsies in NSCLC

September 20th 2022

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Approaches to Biomarker Testing in NSCLC

September 12th 2022

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

Biomarker Testing in NSCLC: Clinical Scenario

September 12th 2022

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

May 25th 2022

Before closing her discussion on advanced non–small cell lung cancer, Ticiana Leal, MD, highlights the possible role of immunotherapy in patients with concomitant KRAS/TP53 mutations.

Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18th 2022

A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.

Overcoming Barriers to Molecular Testing in NSCLC

May 18th 2022

After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.

Optimizing Use of Molecular Testing in Advanced NSCLC

May 11th 2022

Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.

Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

May 11th 2022

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

Dr. Leal on the Utilization of PD-1/PD-L1 Inhibitor Monotherapy in Lung Cancer

February 21st 2022

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC

December 2nd 2021

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

August 25th 2020

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Evidence Builds for Immunotherapy Combos in SCLC

January 10th 2018

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.